Vigabatrin.
Michelucci
R
R
Neurological Clinic, University of Bologna, School of Medicine, Italy.
Tassinari
C A
CA
D000293:Adolescent; D000328:Adult; D000614:Aminocaproates / Q000009:adverse effects / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004311:Double-Blind Method; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D004569:Electroencephalography / Q000187:drug effects; D004831:Epilepsies, Myoclonic / Q000188:drug therapy; D004828:Epilepsies, Partial / Q000188:drug therapy*; D005071:Evoked Potentials / Q000187:drug effects; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D016037:Single-Blind Method; D020888:Vigabatrin
D000614:Aminocaproates; D000927:Anticonvulsants; D015507:Drugs, Investigational; D020888:Vigabatrin